CBD demonstrated antimicrobial activity against extensively drug-resistant Acinetobacter baumannii and synergized with antibiotics, reducing their needed concentrations by up to 1,000-fold.
Infectious disease researchers, antimicrobial resistance scientists, ICU physicians, and anyone interested in novel approaches to fighting superbugs.
What the researchers found
CBD synergized with gentamicin, meropenem, and colistin against XDR A. baumannii, reducing effective antibiotic concentrations up to 1,000-fold. CBD caused rapid concentration-dependent killing through extensive membrane damage, confirmed by electron microscopy.
Why it matters
Extensively drug-resistant bacteria are a global health crisis. CBD's ability to synergize with existing antibiotics — potentially making them effective again at much lower doses — represents a novel approach to antimicrobial resistance.
The numbers in context
26 XDR A. baumannii isolates from ICU devices. CBD MIC: 3.9 to >500 µg/mL. Synergy with gentamicin, meropenem, colistin reduced effective concentrations up to 1,000-fold. Complete bacterial clearance at 4× MIC within 2 hours.
How the study worked
In vitro study testing CBD against 26 XDR A. baumannii ICU isolates using MIC/MBC determination, checkerboard synergy assays, biofilm inhibition/eradication, time-kill studies, membrane integrity assays, and scanning electron microscopy.
What this study cannot tell us
In vitro study only — achievable tissue concentrations of CBD may limit in vivo effectiveness. MIC range was very wide (3.9-500+ µg/mL), suggesting variable effectiveness. No animal infection model tested.
How to read the evidence
Comprehensive in vitro characterization with multiple complementary assays, but no animal model validation limits clinical translation.
When this study was published
Recent study adding to growing evidence of CBD's antimicrobial potential, particularly relevant as antibiotic resistance intensifies globally.
The bigger picture
The antimicrobial resistance crisis needs novel approaches. CBD's membrane-disrupting mechanism is fundamentally different from conventional antibiotics, making cross-resistance unlikely and combination therapy a promising strategy.
Questions still open
- Can CBD concentrations sufficient for antibacterial synergy be achieved in patients? Would topical CBD-antibiotic combinations be feasible for wound infections?
Common questions
Can CBD fight antibiotic-resistant bacteria?
How does CBD kill bacteria?
Read the original research
Potential of Cannabidiol (CBD) to overcome extensively drug-resistant Acinetobacter baumannii.
BMC complementary medicine and therapies, 25(1), 308
Citation
Yosboonruang, Atchariya; Kiddee, Anong; Siriphap, Achiraya; Pook-In, Grissana; Suwancharoen, Chittakun; Duangjai, Acharaporn; Praphasawat, Ratsada; Reuk-Ngam, Nanthawan; Nawong, Siriwan; Rawangkan, Anchalee. (2025). Potential of Cannabidiol (CBD) to overcome extensively drug-resistant Acinetobacter baumannii.. BMC complementary medicine and therapies, 25(1), 308. https://doi.org/10.1186/s12906-025-05056-w
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk
- THC and Antibiotics: Is It Safe to Use Cannabis While on Antibiotics